Network TodayNetwork Today
    What's Hot

    Greene, Gaetz take shots at presidential hopeful Nikki Haley during Trump rally over foreign policy, appeal

    March 26, 2023

    Off-duty Orlando firefighter honored after saving deputy from burning patrol car: ‘Heroic actions’

    March 26, 2023

    Explosion at R.M. Palmer chocolate factory in Pennsylvania leaves 3 dead, company offers condolences

    March 26, 2023
    Facebook Twitter Instagram
    • About
    • Privacy Policy
    • Terms
    • Contact
    Facebook Twitter Instagram
    Sunday, March 26
    Network TodayNetwork Today
    • Home
    • News
    • Politics
    • Business
    • Energy
    • Technology
    • Health
    • Lifestyle
    • Sports
    Network TodayNetwork Today
    Home » Decision Looms That Could Determine Fate of Alzheimer’s Drug

    Decision Looms That Could Determine Fate of Alzheimer’s Drug

    December 31, 20212 Mins Read Business
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Posts supporting coverage include comments from people who have consulted for Biogen, like Dr. Jeffrey Cummings, a research professor in the department of brain health at the University of Nevada Las Vegas. He wrote that the drug “prolongs the mental life of our declining patients,” adding, “Medicare should unequivocally support coverage for aducanumab, and they should do it as soon as possible.”

    Dr. Cummings and several others who earned fees from Biogen were among 25 signatories of another letter on the site. Supporting comments also came from officials of the Infusion Access Foundation and Eli Lilly, which has developed a similar anti-amyloid drug.

    One neurologist, Dr. David Weisman, who said he was not involved with aducanumab’s trials but had worked with other anti-amyloid drugs, wrote that Medicare should require safety monitoring and medical expertise. But because the F.D.A. approved Aduhelm, he wrote, whether to use it “should be left to individual patients, family members and physicians.”

    Commenters who were opposed to coverage or wanted it tightly restricted cited many reasons. Besides inadequate evidence of benefit, they mentioned inequities that could worsen because Medicare coverage wouldn’t include all treatment costs; unknowns about Aduhelm’s effects on nonwhite patients, since most trial participants were white; and risks that profit-seeking clinics could prey on the desperation of patients and families.

    One letter, signed by 180 Alzheimer’s doctors, raised numerous issues, including “harms that people may experience on aducanumab in the real world, outside of a clinical trial setting” given that participants in the drug’s clinical trials were “younger and in earlier stages of cognitive decline, had fewer comorbidities, and were much better monitored than patients will be under conditions of broad Medicare coverage.”

    An author of that letter, Dr. Michael Greicius, medical director of the Stanford Center for Memory Disorders, said, “I’m still quietly hoping that January is going to roll around and they’re going to say: ‘Look, we’re not going to cover this. The evidence is too poor.’”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Esther Perel’s Business Is Your Business

    March 26, 2023

    President Is Ousted in United Auto Workers Election

    March 25, 2023

    Germany and E.U. Agree to Exception in Planned Ban on Combustion Engines

    March 25, 2023

    The Banking Industry’s Go-to Crisis Adviser

    March 25, 2023

    When Your Career, and Retirement, Are the Family’s Business

    March 25, 2023

    I Took Over My Father’s Finances at 25. The Lessons Were Hard-Won.

    March 25, 2023
    Trending

    Greene, Gaetz take shots at presidential hopeful Nikki Haley during Trump rally over foreign policy, appeal

    March 26, 2023

    Off-duty Orlando firefighter honored after saving deputy from burning patrol car: ‘Heroic actions’

    March 26, 2023

    Explosion at R.M. Palmer chocolate factory in Pennsylvania leaves 3 dead, company offers condolences

    March 26, 2023

    Esther Perel’s Business Is Your Business

    March 26, 2023
    Latest News

    Abducted Eliza Fletcher: Family of missing mother makes plea for public’s help in locating Eliza

    September 4, 2022

    Missing Minnesota 6-year-old’s phone found in Mississippi River Park days after mother’s suicide, police say

    July 6, 2022

    Paladino Draws Backlash for Calling Hitler ‘the Kind of Leader We Need’

    June 9, 2022

    Pat McCormick, Olympic Diving Champion, Is Dead at 92

    March 12, 2023

    White House not saying when the Inflation Reduction Act will begin to cut inflation

    August 16, 2022

    A super PAC aligned with the Senate G.O.P. cuts off TV ads in New Hampshire.

    October 21, 2022

    Network Today is one of the biggest English news portal, we provide the latest news from all around the world.

    We're social. Connect with us:

    Facebook Twitter Instagram Pinterest YouTube
    Recent

    Greene, Gaetz take shots at presidential hopeful Nikki Haley during Trump rally over foreign policy, appeal

    March 26, 2023

    Off-duty Orlando firefighter honored after saving deputy from burning patrol car: ‘Heroic actions’

    March 26, 2023

    Explosion at R.M. Palmer chocolate factory in Pennsylvania leaves 3 dead, company offers condolences

    March 26, 2023
    Featured

    Instacart Is Said to Pull Plans to Go Public This Year

    October 21, 2022

    Atlanta PD releases bodycam footage after accusations of excessive force in neighborhood trying to leave city

    August 15, 2022

    U.S. Added 223,000 Jobs in December, a Slight Easing in Pace

    January 6, 2023
    Copyright ©️ All rights reserved | Network Today
    • About
    • Privacy Policy
    • Terms
    • Contact

    Type above and press Enter to search. Press Esc to cancel.